Derek DiRocco - Jun 9, 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role: Director
Signature: /s/ Adi Osovsky, as Attorney-in-Fact
Stock symbol: ITOS
Transactions as of: Jun 9, 2022
Transactions value $: $0
Form type: 4
Date filed: 6/10/2022, 07:48 PM
Previous filing: Jun 3, 2022
Next filing: Nov 9, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITOS	Stock Option (Right to Buy)	Award	$0	+17.5K		$0.00	17.5K	Jun 9, 2022	Common Stock	17.5K	$18.78	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.

Content

This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and the RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund and the Nexus Fund. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.